Ropivacaine Readyfusor®

Assessment Status Rapid Review Complete
Drug Ropivacaine Readyfusor®
Brand Ropivacaine Readyfusor®
Indication For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.
Assessment Process
Rapid review commissioned 09/11/2018
Rapid review completed 13/12/2018
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price. 

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.